The Essential

Why Biotech Struggles to Finish What It Starts

As more drugs stall between early data and approval, Geoffrey Meyerson’s Banyan BioInnovations is testing a new investment approach for biotech’s most expensive and underfunded phase.

Related Content

SPONSORED BY CME GROUP

Dollar Reasserts Itself as Global Tensions Shift Currency Markets

After a year of selling pressure, the dollar recently reversed course. Is this a short-term bounce or the beginning of a sustained reversal?

What Drives the U.S.-Brazil Soybean Price Spread?

Brazil's soybean exports could almost match total U.S. production this year. How could this dynamic impact global soybean price risk?

Why Geopolitical Risk is Fueling the Dollar’s Surge

As traditional safe havens defy historical patterns, the U.S. dollar has emerged as the dominant refuge. CME Group Chief Economist Erik Norland explains.

Job Board – For Investors Only